Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence.

Depression commonly accompanies cancer, but standard antidepressants often work poorly. This review argues that cancer-related depression has distinct biological causes—including inflammation, stress hormone dysregulation, disrupted serotonin pathways, and glutamate toxicity—and that treatments should target those mechanisms. Early evidence suggests that anti-inflammatory drugs like celecoxib, glutamate modulators like ketamine, and atypical antidepressants such as mirtazapine may be more effective than conventional SSRIs or tricyclics, which have shown inconsistent results. The review calls for a personalized, mechanism-based approach rather than a one-size-fits-all model.

Study at a glance

Abstract

Depression is a prevalent comorbidity in cancer, yet conventional treatments show inconsistent efficacy. This review sought to provide a mechanism-based framework for managing cancer-related depression by exploring its unique pathophysiology and evaluating promising pharmacotherapies based on their alignment with these biological pathways. This narrative review synthesized evidence on promising pharmacotherapies based on their ability to target the core biological mechanisms of cancer-related depression, including pro-inflammatory cytokine activity, hypothalamic-pituitary-adrenal axis hyperactivity, serotonin pathway disruption via indolamine-2,3-dioxygenase activation, and glutamate excitotoxicity. Interventions directly targeting inflammation (e.g., celecoxib) and glutamate modulation (e.g., ketamine) demonstrated encouraging early evidence. The effect of ketamine can also be due to its anti-inflammatory properties. Atypical antidepressants, such as mirtazapine, and the serotonergic psychedelic psilocybin also showed promising but preliminary benefits. In contrast, conventional selective serotonin reuptake inhibitors and tricyclic antidepressants yielded conflicting results. Other agents, including the psychostimulant methylphenidate, showed utility for specific symptoms like fatigue. A personalized, mechanism-informed approach targeting the core pathophysiological cascade of inflammation, hypothalamic-pituitary-adrenal axis hyperactivity, and glutamate excitotoxicity is essential for effectively managing depression in patients with cancer. This represents a necessary paradigm shift away from a one-size-fits-all treatment model.